Twice-daily aspirin for acute coronary syndrome with suspected aspirin resistance may be an excessive dosing strategy without clear clinical benefit.
Absolute Event Rate: 0% vs 0%
This editorial refers to ‘Aspirin dosing after acute coronary syndrome with suspected aspirin resistance: the ANDAMAN trial’, by J.-G. Dillinger et al., ht
McCarthy et al. (Thu,) reported a other. Twice-daily aspirin for acute coronary syndrome with suspected aspirin resistance may be an excessive dosing strategy without clear clinical benefit.